FT : Reform UK’s Mayfair fundraiser attracts ‘disgruntled’ ex-Tory donors

Reform UK’s Mayfair fundraiser attracts ‘disgruntled’ ex-Tory donors
Attendees paid five-figure sums to attend dinner hosted by Nigel Farage on Tuesday

More than half a dozen major former Conservative donors paid five-figure sums to attend a lavish fundraiser for Reform UK that raised more than £1mn on Tuesday evening.

Past Tory supporters Bassim Haidar and Mohamed Amersi confirmed their presence, and that they had each paid £25,000 for a VIP ticket to the event in order to sit at the top table.

Haidar said there were at least eight significant former Conservative donors including himself at the event, while Amersi estimated there were many more “disgruntled Tory donors” at the gathering of about 100 people.

Haidar, a Nigerian-born Lebanese entrepreneur who has given £675,000 to the Conservatives in the past two years, told the FT the event was “a valuable opportunity to learn more about the party’s mission, and I believe they have a good one to ‘make the UK great again’.”

He said it was “worth considering them as a strong alternative” to the Tories, whose crackdown on non-doms prompted vocal criticism from Haidar last year.

Fellow tycoon Amersi, a UK citizen born in Kenya, said the party “certainly appeared far more electable than I would ever have imagined, and Farage was inspirational.” He added: “The energy was electric.”

He said Nigel Farage’s links to Donald Trump were an “added bonus” and praised property magnate Nick Candy, the former Tory donor who became Reform’s treasurer last month.

Amersi, who has given more than £500,000 to the Tories since 2018, said he remained a Conservative member and would be attending a cocktail party it was hosting on Wednesday night in London, as he wished to keep abreast of developments.

But he said the Tories were “losing momentum” and accused party leader Kemi Badenoch of having “no policies, no outreach, no connectivity”, adding that she “doesn’t know what ground she is occupying”.

Asked about past Tory donors attending the Reform dinner this week, Badenoch’s spokesperson said on Wednesday: “There are lots of donors out there and we’re looking for new donors all the time, bringing donors back to the party, so we are very confident about our fundraising.”

They added that the Tory leader is getting the party back on a sure financial footing ready to fight the local elections in May.

Myles Barclay, a young member of the Barclay banking family, and Andrew Reid, the British horse race trainer and former treasurer of the UK Independence party, also attended the dinner, according to two people who attended the event. Neither responded to a request for comment.

Other partygoers paid £10,000 for a seat at the dinner at Oswald’s, an exclusive private members’ club in Mayfair owned by Robin Birley.

Birley himself paid for the food at the event, according to two people briefed on the matter.

Guests were served Dom Pérignon 2012 and Nyetimber English sparkling wine, alongside a menu including lobster and avocado, sea bass, and tarte Tropezienne.

Forms requesting additional donations of between £1,000 to £10,000 were left on the tables.

Farage addressed the crowd, declaring “there is no ‘wokery’ in this room”, according to one partygoer.

He set out the party’s plans to make major gains in the Welsh Senedd elections next year. Reform is set to benefit from changes to the electoral system for the Senedd that will make the result more proportional.

Reform came second in 13 of 32 Welsh constituencies at the general election last year, and secured 17 per cent of votes, though it did not win a single seat.

Oliver Lewis, the party’s Welsh spokesperson, said this month that he believed Reform could form the new Senedd government in 2026.

The dinner is the latest signal of Reform’s momentum, after it overtook the Tories in the polls. The latest average shows Farage’s party is one point ahead of the Conservatives and just three points behind Labour.

FT : Renault urges Nissan to secure higher premium from Honda

Renault urges Nissan to secure higher premium from Honda
Executives at French shareholder visit Japan, seeking to benefit from a merger of the two Japanese carmakers

Renault has urged Nissan to negotiate a higher premium from Honda as the French group seeks to benefit from a merger of the two Japanese groups that would create the world’s third-largest carmaker by sales.

According to people with knowledge of the discussions, senior executives at Renault visited Japan to meet Nissan over the past two days to relay its view on the transaction as the two Japanese rivals iron out details of the merger.

Renault has not spoken in detail about the proposed deal but the company has been open to a merger between the two Japanese groups as it aims to sell down its stake in the crisis-hit Nissan.

Nissan and Renault restructured their 25-year alliance in 2023 following constant infighting over their capital structure. Currently, Renault holds a 36 per cent stake in Nissan, including a remaining 18.7 per cent in a French trust, which it has been whittling down. People close to Renault have said the company is open to selling some of its shares in Nissan to Honda if the deal materialised.

During the latest discussions with Nissan, Renault executives called on Nissan not to drag out its talks with Honda in order to focus on reviving its business, one person close to the situation said. As part of its turnaround efforts, Nissan has said it plans to cut 9,000 jobs and a fifth of its production capacity.

“When looking at relative sizes, projected governance and industrial integration, we are talking in reality about Honda taking control of Nissan,” the person added, calling for a “control premium” to be recognised as part of the deal.

Repeating a statement made when Nissan and Honda announced a memorandum of understanding in December, Renault said: “As the main shareholder of Nissan, Renault Group will consider all options based on the best interests of the group and its stakeholders.”

Under the MoU, Honda and Nissan aim to reach a definitive merger agreement for a holding company by the end of June, including fixing the merger ratio.

Honda chief executive Toshihiro Mibe said at the press conference unveiling the talks, that the share ratio would be “decided on the results of due diligence and third-party valuations with reference to the average closing share prices over a certain period prior to the announcement of the MoU”.

Mibe also said that the “majority” of board members of the holding company would be appointed by Honda, in effect admitting that his group would take control, while denying it was rescuing crisis-stricken Nissan.

“Honda would take the lead in pushing this forward in the initial stages,” he said, adding that the company would protect the Nissan brand.

Nissan insiders are concerned about the impact of a potential merger on its brand, citing previous cases of Japan-on-Japan deals such as the Sanyo and Panasonic transaction where the Sanyo brand all but disappeared after the takeover.

Honda announced a hefty ¥1.1tn ($7bn) share buyback on the day of the formal launch of deal talks in an attempt to boost its share price, strengthening its hand in the negotiations.

Nissan declined to comment. Honda did not immediately respond to a request for comment.

WSJ : KKR Builds Stake in Medical-Supply Company, Reaches Deal for Board Seats

KKR Builds Stake in Medical-Supply Company, Reaches Deal for Board Seats
Private-equity firm will have a 12% stake in Henry Schein, with option to buy more

The private-equity firm KKR KKR 3.63%increase; green up pointing triangle has taken a big stake in the medical- and dental-supply company Henry Schein HSIC -0.77%decrease; red down pointing triangle and plans to work with the company to improve its operations.

The details
KKR has amassed a large stake in the company and announced a deal Wednesday that includes increasing that stake to 12% with the option to buy up to 2.9% more in the future, confirming an earlier Wall Street Journal report. Henry Schein has agreed to give the private-equity firm two board seats.

Henry Schein, which has a market capitalization of about $9.5 billion, distributes medical and dental supplies to customers worldwide. The Melville, N.Y., company has been the subject of an activist campaign by Ananym Capital Management, which had been focused on CEO succession planning.

“This just shows that, when you apply pressure to the right place, a variety of good things become possible,” said Charlie Penner, one of Ananym’s co-founders, alongside Alex Silver.

Shares of Henry Schein haven’t moved much in recent years, while the broader market has surged. Investors have soured on the company’s acquisition and integration strategy. The stock was up in premarket trading Wednesday.

“This is a role we can play, being a long-term shareholder to a company truly under attack from activists,” said Pete Stavros, KKR’s global co-head of private-equity. He said the firm would be open to making similar investments in companies beset by activists if it has a good relationship with management and can secure formal governance rights.

KKR will also be working with Henry Schein to explore the possibility of implementing an employee-ownership model, something the private-equity firm has done across its portfolio, the companies said.

The context
Henry Schein CEO Stanley Bergman has been at the helm since 1989. A representative from KKR will join a board committee that has been working on CEO succession planning, the people said.

The deal represents a twist on a traditional corporate-defense strategy. Companies sometimes work with a friendly buyer to keep a hostile buyer at bay. Rarely, if ever, has that “white knight” role been played by a private-equity firm.

Private-equity firms typically take control of a company. For public companies, that usually means paying a significant premium over where the stock is trading to take it private. KKR was able to amass its stock position at market prices.

Doing a full buyout of a company of Henry Schein’s size would also likely require KKR to bring in one or more rival firms as a partner. These so-called club deals have an uneven record because firms often disagree over strategy.

KKR, which manages more than $620 billion in assets, has experience in the dental business. It owns the dental groups Heartland Dental and 123Dentist. Its portfolio company Internet Brands also owns a dental-software company with Henry Schein through a joint venture.

WSJ : Startup Castelion Raises $100 Million for Hypersonic Strike Weapons

Startup Castelion Raises $100 Million for Hypersonic Strike Weapons
The debt-and-equity funding is the latest sign venture capitalists have embraced the superfast weapons

Silicon Valley’s enthusiasm for superfast weapons has picked up speed, with defense-tech startup Castelion raising $100 million through debt and equity to build hypersonic missile systems.

The company is vying to sell long-range strike weapons to the U.S. military. Castelion is part of an increasingly well-funded sector of venture-backed defense companies. Many are hopeful the new Trump administration and Elon Musk’s influence with the president will yield more government contracts for startups.

“There will be more support for awarding contracts to nontraditional players,” said Sean Pitt, Castelion’s co-founder. The administration has given the Pentagon “the freedom to lean into new companies.”

Castelion raised $70 million from venture investors and $30 million in debt to help finance a new manufacturing plant to add to its facilities in California and Texas. The funding round, led by Lightspeed Venture Partners, brings the company’s total funding to $114 million. Andreessen Horowitz also invested.

A number of startups are focused on building hypersonic-speed aircraft as well as launching services and engines. Castelion is pitching an entire weapons system. It builds the whole aircraft, from the solid rocket motors to the electronics. It may venture into building the warheads, although now the company buys them.

The Defense Department has considered hypersonics a national-security imperative for more than a decade. Despite spending billions of dollars on the effort, it has failed to develop battlefield-ready technology.

Castelion says its frequent flight tests, quick engineering upgrades and economical manufacturing will produce cheaper and better hypersonic weapons. It does about three test flights a month in the California desert.

Hypersonic weapons, defined as a projectile that flies at least five times the speed of sound, can be launched from great distances, maneuver and evade most air defenses. They became a top Defense Department priority during President Trump’s first administration. A 2021 test flight by China, which launched a weapon that circled the globe at 20 times the speed of sound or faster, alarmed Washington. Last year, the Biden administration added hypersonics to its list of critical and emerging technologies.

The Army missed its goal of fielding a hypersonics weapon in 2023 after testing failures, and pushed its deadline back. The Army didn’t respond to a request for comment.

A hypersonics program the Air Force estimated would become operational in 2022 hasn’t materialized, and the service is working on another program that it says will produce a weapon in 2027. An Air Force spokeswoman said the service is working on other programs and collaborating with startup defense companies and providing them with opportunities to demonstrate their technology.

Many in the industry hope Trump’s shake-up of Washington agencies, the technology industry’s coziness with the president, and influence from Musk—himself the founder of the largest venture-backed defense-tech company—will bring attention and money to hypersonics.

Castelion’s three founders were each previously in senior positions at SpaceX, and roughly half the company’s 60 employees joined from Musk’s firm. The founders said they haven’t had contact with Musk since starting Castelion in 2022.

Castelion said it would have a finished product ready for the military in 2027 and will have its first hypersonic-speed test flight for its weapon this summer. It has been awarded more than $22 million in federal government contracts, most from the Air Force.

>>> US Research Calls II

Research Calls II
  • Upgrades:
    • Beam Therapeutics (BEAM) upgraded to Overweight from Neutral at Cantor Fitzgerald
    • Open Lending (LPRO) upgraded to Buy from Hold at Needham; tgt $7
    • Nextracker (NXT) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $60
    • Sanmina (SANM) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $92
    • Western New England Bancorp (WNEB) upgraded to Buy from Neutral at Seaport Research Partners; tgt $11
  • Downgrades:
    • Apple (AAPL) downgraded to Perform from Outperform at Oppenheimer
    • DarioHealth (DRIO) downgraded to Hold from Buy at TD Cowen; tgt lowered to $1
    • Galiano Gold (GAU) downgraded to Market Perform from Outperform at BMO Capital Markets
    • Infosys (INFY) downgraded to Hold from Buy at Erste Group
    • Paragon 28 (FNA) downgraded to Mkt Perform from Outperform at William Blair
    • Royal Bank of Canada (RY) downgraded to Hold from Buy at Erste Group
  • Others:
    • Larimar Therapeutics (LRMR) initiated with a Buy at Truist; tgt $18
    • OnKure Therapeutics (OKUR) initiated with a Buy at JonesResearch
    • Spotify (SPOT) resumed with a Buy at Erste Group

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • AT&T (T) upgraded to Buy from Hold at DZ Bank; tgt $27
    • Coinbase Global (COIN) upgraded to Outperform from Neutral at Mizuho; tgt raised to $290
    • NBT Bancorp (NBTB) upgraded to Overweight from Equal-Weight at Stephens; tgt $53
    • Verizon (VZ) upgraded to Buy from Hold at DZ Bank; tgt $40
  • Downgrades:
    • Datadog (DDOG) downgraded to Hold from Buy at Stifel; tgt lowered to $140
    • Leap Therapeutics (LPTX) downgraded to Neutral from Outperform at Robert W. Baird; tgt lowered to $1.25
    • Leap Therapeutics (LPTX) downgraded to Neutral from Buy at H.C. Wainwright
    • Moderna (MRNA) downgraded to Neutral from Buy at Goldman; tgt lowered to $51
    • Third Coast Bancshares (TCBX) downgraded to Mkt Perform from Outperform at Keefe Bruyette; tgt raised to $42
    • Tenaris (TS) downgraded to Underperform from Neutral at BofA Securities
    • Transcat (TRNS) downgraded to Perform from Outperform at Oppenheimer
  • Others:
    • Brighthouse Financial (BHF) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $85
    • Curbline Properties (CURB) initiated with an Equal-Weight at Morgan Stanley; tgt $27
    • MicroStrategy (MSTR) initiated with an Outperform at Mizuho; tgt $515
    • Millicom International Cellular (TIGO) initiated with an Equal-Weight at Morgan Stanley; tgt $32
    • Rivian Automotive (RIVN) initiated with an Underperform at Bernstein; tgt $6.10

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • MANH -23.6%, LC -21%, PB -12.5%, QRVO -7.2%, DHR -6.4%, CLBK -5.8%, TEVA -5.5%, PKG -5.4%, VSCO -5%, MSCI -4.5%, WNC -4.1%, RNST -3.1%, SYK -2.3% (also to sell its US spinal implants business; also CFO to retire), NPCE -2.1%, OTIS -2%, LII -1.9%, GD -1.8%, VBTX -1.6%, NRIX -1%, BXP -0.9%, MBIN -0.9%, SBSI -0.7%, EXP -0.7%
Other news:
  • ZNTL -27.9% (to restructure operations and R&D, expects 40% workforce reduction; presents updated azenosertib monotherapy clinical data from its ZN-c3-001)
  • DHX -3.1% (adopts shareholder rights plan)
  • MRVI -2.5% (to acquire I.P. assets from Molecular Assemblies)
  • SMPL -2.1% (CFO to retire, names new CFO)
  • AXL -2.1% (to form combination with Dowlais for $1.44 billion in cash and stock; provides FY24 outlook)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • NXT +21.8%, FFIV +13.3%, EAT +10.5%, TMUS +7.4%, ASML +5.9%, GLW +5.4%, EXTR +5.2%, VIRT +4.5%, LRN +4.3%, SF +4.3%, SMG +4.2%, LOGI +4.1%, VFC +2.7%, FCF +2.3%, SBUX +2.1%, SLGN +2.1%, NAVI +2%, ASH +1.2%, ADP +1.2%, GPI +1.1%,
Other news:
  • CGEM +14.8% (Cullinan Therapeutics, Taiho Pharmaceutical and Taiho Oncology Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy)
  • PACK +10.3% (details Amazon.com (AMZN) Transaction Agreement for warrant to purchase common stock)
  • FNA +9.2% (Paragon 28 to be acquired by Zimmer Biomet for upfront payment of $13.00 per share)
  • AZUL +8.8% (concludes restructuring process; eliminating $2.1 billion in debt and financial obligations and receiving $525 million in new capital)
  • AHH +3.7% (updates strategic steps in its balance sheet management strategy)
  • HSIC +3.2% (confirms strategic investment by KKR (KKR); sees Q4 EPS and revs below consensus; provides FY25 guidance; authorized an increase of $500 million to the company's stock repurchase program)
  • HAFC +2.7% (increases dividend)
  • SYNA +2.1% (SYNA accelerates Edge AI strategy by signing licensing agreement with AVGO)
  • ASPN +2% (resolves patent dispute with AMA)
  • SEDG +1.9% (in sympathy with strong NXT earnings)
  • AVGO +1.8% (SYNA accelerates Edge AI strategy by signing licensing agreement with AVGO)
  • ETNB +1.8% (prices $250.0 mln offering of common stock and pre-funded warrants)
  • SES +1.8% (signed a non-binding Memorandum of Understanding with AISPEX)
  • ENPH +1.7% (in sympathy with strong NXT earnings)
  • FSLR +1.7% (in sympathy with strong NXT earnings)
  • SONY +1.6% (approved a new management structure effective April 1, 2025 at a meeting of its Board of Directors held today)
  • NOG +1.5% (increases dividend)
  • ULCC +1.5% (confirms that it has had preliminary confidential discussions with Spirit and has made a proposal to combine with Spirit (SAVE / SAVEQ))
  • RUN +1.1% (in sympathy with strong NXT earnings)
  • AKRO +1% (prices offering of common stock and pre-funded warrants)

>>> Europe : Brokers Upgrades & Downgrades - 29th of January 2025 V3(++)

>>> Up
* Brooks Macdonald Raised to Buy at Shore Capital; PT 1,900 pence
* Carl Zeiss Meditec Raised to Neutral at Goldman; PT 60 euros
* Elisa Raised to Accumulate at Inderes; PT 48 euros
* EssilorLuxottica Raised to Outperform at RBC; PT 290 euros
* ID Logistics Group SACA Raised to Buy at Stifel; PT 475 euros
* ID Logistics Group SACA Raised to Buy at IDMidcaps; PT 454 euros (+)
* LVMH PT Raised to 840 euros from 800 euros at TD Cowen (+)
* Revenio Raised to Buy at SEB Equities; PT 35 euros
* Rheinmetall PT Raised to 920 euros at Hauck & Aufhaeuser (+)
* Severn Trent Raised to Buy at Kepler Cheuvreux (+)
* Smartoptics Group Raised to Buy at ABG; PT 25 kroner (+)
* Wacker Chemie Raised to Buy at DZ Bank; PT 81 euros (+)

>>> Down
* Atlas Copco Cut to Hold at Nordea
* Hexagon Cut to Reduce at Inderes; PT 120 kronor
* LVMH Cut to Neutral at Grupo Santander; PT 686 euros
* Magyar Telekom Cut to Hold at Erste Group; PT 1,450 forint
* Moderna Cut to Neutral at Goldman (+)
* Pacific Assets Cut to Hold at Stifel (+)
* Riber Cut to Hold at TP ICAP Midcap; PT 3.50 euros (+)
* Siemens Energy Cut to Hold at Bankhaus Metzler; PT 56 euros (++)
* Zealand Pharma Cut to Hold at SEB Equities; PT 800 kroner

>>> Initiation
* Befesa Rated New Buy at Bankhaus Metzler; PT 34.20 euros (++)
* Hafnia Rated New Neutral at SpareBank; PT 63 kroner
* HIK IM Rated New Outperform at EnVent S.p.A.; PT 1.20 euros
* Mitie Rated New Buy at Berenberg; PT 160 pence
* Rivian Rated New Underperform at Bernstein
* Scatec Rated New Outperform at Oddo BHF; PT 105 kroner
* Serco Rated New Buy at Berenberg; PT 200 pence
* Vitrolife Reinstated Buy at Nordea; PT 272 kronor
* Zurich Airport Rated New Hold at Jefferies; PT 236 Swiss francs

>>> Call
* DeepSeek May Catalyze European Stocks Relative Performance: Citi
* Goldman Strategists Say AI Selloff Isn’t Start of Bear Market (+)
* JPMorgan Sees Cheap AI Models as Net Positive for Global Stocks
* WH Smith North America Growth Acceleration a Key Positive: RBC (+)